Vertex Pharmaceuticals Incorporated

178 articles about Vertex Pharmaceuticals Incorporated

• Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

  4/10/2024

  Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.

• Vertex to Participate in Upcoming March 2024 Investor Conferences

  2/20/2024

  Vertex Pharmaceuticals Incorporated announced that Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in two upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 10:30 a.m. ET.

• European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

  2/13/2024

  Vertex Pharmaceuticals Incorporated announced that the European Commission has granted conditional marketing authorization to CASGEVY™, a CRISPR/Cas9 gene-edited therapy.

• Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

  1/30/2024

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain.

• Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA

  12/12/2022

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease.

• Vertex Reports Third Quarter 2022 Financial Results

  10/27/2022

  Vertex Pharmaceuticals Incorporated reported consolidated financial results for the third quarter ended September 30, 2022 and increased its full year 2022 revenue guidance.

• Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

  9/27/2022

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that Vertex has concluded discussions with the U.S. Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

• Vertex Appoints Jonathan Biller as Chief Legal Officer

  9/8/2022

  Vertex Pharmaceuticals Incorporated announced that Jonathan Biller has been appointed Chief Legal Officer, effective September 19, 2022.

• Vertex Reports Second Quarter 2022 Financial Results

  8/4/2022

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022 and updated its full year 2022 financial guidance.

• Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes

  7/11/2022

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.

• Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

  6/11/2022

  Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announce presentation of new data on exa-cel, formerly known as CTX001™, from CLIMB-111, CLIMB-121 and CLIMB-131 highlighting the potentially transformative profile of this investigational therapy for people with transfusion-dependent beta thalassemia or severe sickle cell disease and provided additional program updates.

• 

  Vertex Kidney Disease Drug Scores FDA Breakthrough Therapy Designation

  6/8/2022

  The FDA granted Breakthrough Therapy Designation to Verttex's candidate inaxaplin (VX-147). for the treatment of APOL1-mediated focal segment glomerulosclerosis.

•  Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15

  6/8/2022

  Vertex Pharmaceuticals Incorporated announced that the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 1:20 p.m. PT.

• Suketu Upadhyay Elected to Vertex Board of Directors

  5/18/2022

  Vertex Pharmaceuticals Incorporated announced that Suketu Upadhyay has been elected to its board of directors as an independent director.

• Vertex Reports First Quarter 2022 Financial Results

  5/5/2022

  Vertex Pharmaceuticals Incorporated reported consolidated financial results for the first quarter ended March 31, 2022 and reiterated full year 2022 product revenue guidance.

• Vertex to Announce First Quarter 2022 Financial Results on May 5

  4/21/2022

  Vertex Pharmaceuticals Incorporated will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.

• Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene

  3/26/2022

  Vertex Pharmaceuticals Incorporated announced that as of 1 April 2022, TRIKAFTA® will be reimbursed on the Australian Pharmaceutical Benefits Scheme for the treatment of cystic fibrosis in people ages 12 years and older who have at least one F508del mutation in the CFTR gene, the most common CF-causing mutation worldwide.

• Vertex to Announce Fourth Quarter 2021 Financial Results on January 26

  1/18/2022

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022 after the financial markets close.

• European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years

  1/11/2022

  Vertex Pharmaceuticals Incorporated announced that the European Commission has granted approval for the label extension of KAFTRIO® in a combination regimen with ivacaftor for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

• Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis

  12/1/2021

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS).